{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:40:23Z","timestamp":1783698023987,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s11011-011-9233-2","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T10:26:17Z","timestamp":1297160777000},"page":"1-8","source":"Crossref","is-referenced-by-count":43,"title":["Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses"],"prefix":"10.1007","volume":"26","author":[{"given":"Anna","family":"Kloska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Jak\u00f3bkiewicz-Banecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Narajczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zyta","family":"Banecka-Majkutewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"W\u0119grzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,9]]},"reference":[{"key":"9233_CR1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10545-009-9029-2","volume":"33","author":"A Arfi","year":"2010","unstructured":"Arfi A, Richard M, Gandolphe C, Scherman D (2010) Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J Inherit Metab Dis 33:61\u201367","journal-title":"J Inherit Metab Dis"},{"key":"9233_CR2","first-page":"13","volume-title":"Genetic metabolic disorders: management, costs and sociomedical aspects","author":"M Beck","year":"2007","unstructured":"Beck M (2007a) Mucopolysaccharidoses: clinical features and management. In: vom Dahl S, Wendel U, Strohmeyer G (eds) Genetic metabolic disorders: management, costs and sociomedical aspects. Deutscher Arzte-Verlag, Cologne, pp 13\u201318"},{"key":"9233_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00439-006-0280-4","volume":"121","author":"M Beck","year":"2007","unstructured":"Beck M (2007b) New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 121:1\u201322","journal-title":"Hum Genet"},{"key":"9233_CR4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.cellbio.22.010605.093433","volume":"22","author":"HE Bulow","year":"2006","unstructured":"Bulow HE, Hobert O (2006) The molecular diversity of glycosaminoglycans shapes animal development. Annu Rev Cell Dev Biol 22:375\u2013407","journal-title":"Annu Rev Cell Dev Biol"},{"key":"9233_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11523-009-0112-2","volume":"4","author":"E Azambuja de","year":"2009","unstructured":"de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M (2009) Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 4:77\u201388","journal-title":"Target Oncol"},{"key":"9233_CR6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/ejhg.2009.144","volume":"18","author":"D Dziedzic","year":"2009","unstructured":"Dziedzic D, Wegrzyn G, Jakobkiewicz-Banecka J (2009) Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Eur J Hum Genet 18:200\u2013205","journal-title":"Eur J Hum Genet"},{"key":"9233_CR7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1476-5381.2009.00565.x","volume":"159","author":"A Friso","year":"2010","unstructured":"Friso A, Tomanin R, Salvalaio M, Scarpa M (2010) Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 159:1082\u20131091","journal-title":"Br J Pharmacol"},{"key":"9233_CR8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF03195237","volume":"48","author":"J Jakobkiewicz-Banecka","year":"2007","unstructured":"Jakobkiewicz-Banecka J, Wegrzyn A, Wegrzyn G (2007) Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet 48:383\u2013388","journal-title":"J Appl Genet"},{"key":"9233_CR9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1423-0127-16-26","volume":"16","author":"J Jakobkiewicz-Banecka","year":"2009","unstructured":"Jakobkiewicz-Banecka J, Piotrowska E, Narajczyk M, Baranska S, Wegrzyn G (2009) Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16:26","journal-title":"J Biomed Sci"},{"key":"9233_CR10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ejhg.2009.143","volume":"18","author":"X Kaidonis","year":"2009","unstructured":"Kaidonis X, Liaw WC, Roberts AD, Ly M, Anson D, Byers S (2009) Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses. Eur J Hum Genet 18:194\u2013199","journal-title":"Eur J Hum Genet"},{"key":"9233_CR11","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1128\/AAC.39.9.1979","volume":"39","author":"M Kato","year":"1995","unstructured":"Kato M, Takeda S, Ogawara S, Takayama S (1995) Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother 39:1979\u20131983","journal-title":"Antimicrob Agents Chemother"},{"key":"9233_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2007.06.022","volume":"224","author":"CB Klein","year":"2007","unstructured":"Klein CB, King AA (2007) Genistein genotoxicity: critical considerations of in vitro exposure dose. Toxicol Appl Pharmacol 224:1\u201311","journal-title":"Toxicol Appl Pharmacol"},{"key":"9233_CR13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1080\/15287390903212212","volume":"72","author":"SJ Kwack","year":"2009","unstructured":"Kwack SJ, Kim KB, Kim HS, Yoon KS, Lee BM (2009) Risk assessment of soybean-based phytoestrogens. J Toxicol Environ Health A 72:1254\u20131261","journal-title":"J Toxicol Environ Health A"},{"key":"9233_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","volume":"4","author":"T Li","year":"2009","unstructured":"Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107\u2013119","journal-title":"Target Oncol"},{"key":"9233_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-60761-454-8_1","volume":"600","author":"J Li","year":"2010","unstructured":"Li J, Richards JC (2010) Functional glycomics and glycobiology: an overview. Methods Mol Biol 600:1\u20138","journal-title":"Methods Mol Biol"},{"key":"9233_CR16","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1021\/jf073520n","volume":"56","author":"N Li","year":"2008","unstructured":"Li N, Liu JH, Zhang J, Yu BY (2008) Comparative evaluation of cytotoxicity and antioxidative activity of 20 flavonoids. J Agric Food Chem 56:3876\u20133883","journal-title":"J Agric Food Chem"},{"key":"9233_CR17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2009.06.013","volume":"98","author":"M Malinowska","year":"2009","unstructured":"Malinowska M, Wilkinson FL, Bennett W et al (2009) Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 98:235\u2013242","journal-title":"Mol Genet Metab"},{"key":"9233_CR18","doi-asserted-by":"crossref","first-page":"e14192","DOI":"10.1371\/journal.pone.0014192","volume":"5","author":"M Malinowska","year":"2010","unstructured":"Malinowska M, Wilkinson FL, Langford-Smith KJ et al (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS ONE 5:e14192","journal-title":"PLoS ONE"},{"key":"9233_CR19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1248\/bpb.28.253","volume":"28","author":"M Matsuo","year":"2005","unstructured":"Matsuo M, Sasaki N, Saga K, Kaneko T (2005) Cytotoxicity of flavonoids toward cultured normal human cells. Biol Pharm Bull 28:253\u2013259","journal-title":"Biol Pharm Bull"},{"key":"9233_CR20","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","volume":"30","author":"PJ Medina","year":"2008","unstructured":"Medina PJ, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30:1426\u20131447","journal-title":"Clin Ther"},{"key":"9233_CR21","first-page":"3421","volume-title":"The metabolic and molecular bases of inherited disease","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3421\u20133452"},{"key":"9233_CR22","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.ejhg.5201623","volume":"14","author":"E Piotrowska","year":"2006","unstructured":"Piotrowska E, Jakobkiewicz-Banecka J, Baranska S et al (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14:846\u2013852","journal-title":"Eur J Hum Genet"},{"key":"9233_CR23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.curtheres.2008.04.002","volume":"63","author":"E Piotrowska","year":"2008","unstructured":"Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A et al (2008) Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp 63:166\u2013179","journal-title":"Curr Ther Res Clin Exp"},{"key":"9233_CR24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1651-2227.2008.01153.x","volume":"98","author":"E Piotrowska","year":"2009","unstructured":"Piotrowska E, Jak\u00f3bkiewicz-Banecka J, Tylki-Szyma\u0144ska A, Czartoryska B, W\u0119grzyn A, W\u0119grzyn G (2009) Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatr 98:743\u2013749","journal-title":"Acta Paediatr"},{"key":"9233_CR25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1203\/01.pdr.0000233037.00707.da","volume":"60","author":"AL Roberts","year":"2006","unstructured":"Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S (2006) Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 60:309\u2013314","journal-title":"Pediatr Res"},{"key":"9233_CR26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2007.06.016","volume":"92","author":"AL Roberts","year":"2007","unstructured":"Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S (2007) Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 92:115\u2013121","journal-title":"Mol Genet Metab"},{"key":"9233_CR27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ymgme.2010.06.008","volume":"101","author":"AL Roberts","year":"2010","unstructured":"Roberts AL, Fletcher JM, Moore L, Byers S (2010) Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA. Mol Genet Metab 101:208\u2013213","journal-title":"Mol Genet Metab"},{"key":"9233_CR28","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.2165\/10489100-000000000-00000","volume":"69","author":"M Sanford","year":"2009","unstructured":"Sanford M, Scott LJ (2009) Gefitinib: a review of its use in the treatment of locally advanced\/metastatic non-small cell lung cancer. Drugs 69:2303\u20132328","journal-title":"Drugs"},{"key":"9233_CR29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.beem.2009.08.001","volume":"23","author":"SI Sherman","year":"2009","unstructured":"Sherman SI (2009) Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 23:713\u2013722","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"9233_CR30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1742-4658.2009.07450.x","volume":"277","author":"K Takeuchi","year":"2010","unstructured":"Takeuchi K, Ito F (2010) EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J 277:316\u2013326","journal-title":"FEBS J"},{"key":"9233_CR31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.chroma.2004.10.048","volume":"1073","author":"TH Tsai","year":"2005","unstructured":"Tsai TH (2005) Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A 1073:317\u2013322","journal-title":"J Chromatogr A"},{"key":"9233_CR32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mehy.2010.07.044","volume":"75","author":"G W\u0119grzyn","year":"2010","unstructured":"W\u0119grzyn G, Jak\u00f3bkiewicz-Banecka J, Narajczyk M, Wi\u015bniewski A, Piotrowska E, Gabig-Cimi\u0144ska M, Kloska A, S\u0142omi\u0144ska-Wojew\u00f3dzka M, Korzon-Burakowska A, W\u0119grzyn A (2010) Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different? Med Hypotheses 75:605\u2013609","journal-title":"Med Hypotheses"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11011-011-9233-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T19:31:27Z","timestamp":1497900687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-011-9233-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["9233"],"URL":"https:\/\/doi.org\/10.1007\/s11011-011-9233-2","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,9]]}}}